Citations

Clear

6273 citation(s) found for "To, Andrew".

CAMKV Autoimmune Paraneoplastic Encephalitis (N1.003)
Gilligan, Michael , Lesnick, Connie , Shah, Maulik , Wittenborn, John S. , Hinson, Shannon R., Mills, John R. , Ζεκερίδου, Αναστασία , Bradshaw, Michael, Ladha, Shafeeq , Wittenborn, John, Dubey, Divyanshu , Pittock, Sean J. , McKeon, Andrew

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204736 Get It

Identification of SKOR2 IgG as a Novel Biomarker of Paraneoplastic Neurologic Syndrome (N1.001)
Kapadia, Ronak K. , Guo, Yong , LaFrance‐Corey, Reghann G., Ζεκερίδου, Αναστασία , McKeon, Andrew, Dasari, Surendra , Mills, John R. , Rezk, Mohamed, Pittock, Sean J. , Knight, Andrew, Gupta, Pranjal , McKeon, Andrew , Dubey, Divyanshu

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204359 Get It

Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid
Redenbaugh, Vyanka , Fryer, James P., Chen, John J. , Greenwood, Tammy M., Gilligan, Michael , Majed, Masoud , McKeon, Andrew , Mills, John R. , López‐Chiriboga, A. Sebastian , Tillema, Jan‐Mendelt , Yang, Binxia , Abdulrahman, Yahya, Guo, Kai , Tajfirouz, Deena , Toledano, Michel , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Gombolay, Grace , Caparó‐Zamalloa, César , Pittock, Sean J. , Dubey, Divyanshu , Pittock, S J , Thakolwiboon, Smathorn , Chia, Nicholas H , McKeon, Andrew , Lopez-Chiriboga, A Sebastian , Vorasoot, Nisa , Valencia Sanchez, Cristina , Tajfirouz, Deena A, Zekeridou, Anastasia , Dubey, Divyanshu , Gombolay, Grace Y , Flanagan, E P , Chen, John J , Dubey, Divyanshu , Gilligan, Michael , Cacciaguerra, Laura , Chia, Nicholas , Vorasoot, Nisa , Valencia-Sánchez, Cristina , Kister, Ilya , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | April 9, 2024 | Volume: 96 | Issue: 1 | Pages: 34-45

10.1002/ana.26931 | PMID 38591875 Get It

Objective The aim of this study was to assess the diagnostic utility of cerebrospinal fluid (CSF) myelin oligodendrocyte glycoprotein antibodies (MOG‐IgG) testing. Methods We retrospectively identified patients for CSF MOG‐IgG testing from January 1, 1996, to May 1, 2023, at Mayo Clinic and other medical centers that sent CSF MOG‐IgG for testing including: controls, 282; serum MOG‐IgG positive MOG antibody‐associated disease (MOGAD), 74; serum MOG‐IgG negative high‐risk phenotypes, 73; serum false positive MOG‐IgG with alternative diagnoses, 18. A live cell‐based assay assessed CSF MOG‐IgG positivity (IgG‐binding‐index [IBI], ≥2.5) using multiple anti‐human secondary antibodies and end‐titers were calculated if sufficient sample volume. Correlation of CSF MOG‐IgG IBI and titer was assessed. Results The pan‐IgG Fc‐specific secondary was optimal, yielding CSF MOG‐IgG sensitivity of 90% and specificity of 98% (Youden's index 0.88). CSF MOG‐IgG was positive in: 4/282 (1.4%) controls; 66/74 (89%) serum MOG‐IgG positive MOGAD patients; and 9/73 (12%) serum MOG‐IgG negative patients with high‐risk phenotypes. Serum negative but CSF positive MOG‐IgG accounted for 9/83 (11%) MOGAD patients, and all fulfilled 2023 MOGAD diagnostic criteria. Subgroup analysis of serum MOG‐IgG low‐positives revealed CSF MOG‐IgG positivity more in MOGAD (13/16[81%]) than other diseases with false positive serum MOG‐IgG (3/15[20%]) ( p = 0.01). CSF MOG‐IgG IBI and CSF MOG‐IgG titer (both available in 29 samples) were correlated (Spearman's r = 0.64, p < 0.001). Interpretation CSF MOG‐IgG testing has diagnostic utility in patients with a suspicious phenotype but negative serum MOG‐IgG, and those with low positive serum MOG‐IgG results and diagnostic uncertainty. These findings support a role for CSF MOG‐IgG testing in the appropriate clinical setting. ANN NEUROL 2024;96:34–45
Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
Masri, Ahmad , Lester, Steven J., Stendahl, John C. , Hegde, Sheila M. , Sehnert, Amy J. , Balaratnam, Ganesh, Fox, Shawna, Wang, Andrew , Wang, Andrew , Sehnert, Amy J , Hegde, Sheila M , Shah, Ashish

Mayo Clinic

Journal of the American Heart Association | April 9, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.030607 | PMID 38591260 Get It

Background The phase 2 PIONEER‐HCM (Phase 2 Open‐label Pilot Study Evaluating Mavacamten in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) study showed that mavacamten improved left ventricular outflow tract gradients, exercise capacity, and symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM), but the results of longer‐term treatment are less well described. We report interim results from the PIONEER‐OLE (PIONEER Open‐Label Extension) study, the longest‐term study of mavacamten in patients with symptomatic obstructive HCM. Methods and Results Patients who previously completed PIONEER‐HCM (n=20) were eligible to enroll in PIONEER‐OLE. Patients received oral mavacamten, 5 mg once daily (starting dose), with individualized dose titration at week 6. Evaluations included serial monitoring of safety, echocardiography, Kansas City Cardiomyopathy Questionnaire–Overall Summary Score, and serum NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels. Thirteen patients enrolled and received mavacamten (median study duration at data cutoff, 201 weeks). Most patients (92.3%) received β‐blockers concomitantly. Treatment‐emergent adverse events were predominantly mild/moderate. One patient had an isolated reduction in left ventricular ejection fraction to 47%, which recovered and remained normal with continued treatment at a reduced dose. At week 180, mavacamten was associated with New York Heart Association class improvements from baseline (class II to I, n=9; class III to II, n=1; and unchanged, n=2), sustained reductions in left ventricular outflow tract gradients (mean [SD] change from baseline: resting, −50 [55] mm Hg; Valsalva, −70 [41] mm Hg), and serum NT‐proBNP levels (median [interquartile range] change from baseline: −498 [−2184 to −76] ng/L), and improved Kansas City Cardiomyopathy Questionnaire–Overall Summary Score (mean [SD] change from baseline: +17 [16]). Conclusions This long‐term analysis supports the continued safety and effectiveness of mavacamten for >3 years in obstructive HCM. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03496168.
Segond Fractures Can Be Identified With Excellent Accuracy Utilizing Deep Learning on Anteroposterior Knee Radiographs
Oeding, Jacob F. , Pareek, Ayoosh , Kunze, Kyle N. , Nwachukwu, Benedict U. , Greditzer, Harry G. , Camp, Christopher L. , Kelly, Bryan T. , Pearle, Andrew D. , Registry, HSS ACL Reconstruction, Camp, Christopher L. , Oeding, Jacob F , Ranawat, Anil S. , Williams, Riley J. , Registry, HSS ACL Reconstruction

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | April 8, 2024 | Volume: 6 | Issue: 3 | Pages: No page available

10.1016/j.asmr.2024.100940 | PMID 39006790 Get It

Purpose To develop a deep learning model for the detection of Segond fractures on anteroposterior (AP) knee radiographs and to compare model performance to that of trained human experts. Methods AP knee radiographs were retrieved from the Hospital for Special Surgery ACL Registry, which enrolled patients between 2009 and 2013. All images corresponded to patients who underwent anterior cruciate ligament reconstruction by 1 of 23 surgeons included in the registry data. Images were categorized into 1 of 2 classes based on radiographic evidence of a Segond fracture and manually annotated. Seventy percent of the images were used to populate the training set, while 20% and 10% were reserved for the validation and test sets, respectively. Images from the test set were used to compare model performance to that of expert human observers, including an orthopaedic surgery sports medicine fellow and a fellowship‐trained orthopaedic sports medicine surgeon with over 10 years of experience. Results A total of 324 AP knee radiographs were retrieved, of which 34 (10.4%) images demonstrated evidence of a Segond fracture. The overall mean average precision (mAP) was 0.985, and this was maintained on the Segond fracture class (mAP = 0.978, precision = 0.844, recall = 1). The model demonstrated 100% accuracy with perfect sensitivity and specificity when applied to the independent testing set and the ability to meet or exceed human sensitivity and specificity in all cases. Compared to an orthopaedic surgery sports medicine fellow, the model required 0.3% of the total time needed to evaluate and classify images in the independent test set. Conclusions A deep learning model was developed and internally validated for Segond fracture detection on AP radiographs and demonstrated perfect accuracy, sensitivity, and specificity on a small test set of radiographs with and without Segond fractures. The model demonstrated superior performance compared with expert human observers. Clinical Relevance Deep learning can be used for automated Segond fracture identification on radiographs, leading to improved diagnosis of easily missed concomitant injuries, including lateral meniscus tears. Automated identification of Segond fractures can also enable large‐scale studies on the incidence and clinical significance of these fractures, which may lead to improved management and outcomes for patients with knee injuries.
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer
Yaeger, Rona , Uboha, Nataliya V. , Pelster, Meredith S. , Bekaii‐Saab, Tanios , Barve, Minal , Saltzman, Joel , Sabari, Joshua K. , Peguero, Julio A. , Paulson, Andrew Scott , Jänne, Pasi A. , Anderes, Kenna , Velastegui, Karen , Yan, Xiaohong , Der‐Torossian, Hirak , Bekaii-Saab, Tanios S , Cruz-Correa, Marcia , Anderes, Kenna , Velastegui, Karen , Yan, Xiaohong , Der-Torossian, Hirak , Klempner, Samuel J , Kopetz, Scott , Cruz‐Correa, Marcia , Klempner, Samuel J. , Kopetz, Scott

Mayo Clinic

Cancer Discovery | April 8, 2024 | Volume: 14 | Issue: 6 | Pages: 982-993

10.1158/2159-8290.cd-24-0217 | PMID 38587856 Get It

Abstract Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. Significance: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897 See co-corresponding author Rona Yaeger discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606282/f27a6e46f4
Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group
Husain, Aliya N. , Chapel, David B. , Attanoos, Richard , Beasley, Mary Beth , Butnor, Kelly J. , Đačić, Sanja , Hiroshima, Kenzo , Hung, Yin P. , Klebe, Sonja , Krausz, Thomas, Khoór, András , Litzky, Leslie A., Nabeshima, Kazuki , Roden, Anja C. , Roggli, Victor L., Schulte, Jefree J. , Sheaff, Michael , Walts, Ann E. , Colby, Thomas V. , Hung, Yin P , Brčić, Luka , Chirieac, Lucian R. , Churg, Andrew , Marchevsky, Alberto M. , Nicholson, Andrew G. , Pavlisko, Elizabeth N. , Sauter, Jennifer L. , Travis, William D. , Tsao, Ming‐Sound

Mayo Clinic

Archives of Pathology & Laboratory Medicine | April 8, 2024 | Volume: 148 | Issue: 11 | Pages: 1251-1271

10.5858/arpa.2023-0304-ra | PMID 38586983 Get It

Context.— Mesothelioma is an uncommon tumor that can be difficult to diagnose. Objective.— To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. Data Sources.— Pathologists involved in the International Mesothelioma Interest Group and others with expertise in mesothelioma contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions.— There was consensus opinion regarding guidelines for (1) histomorphologic diagnosis of mesothelial tumors, including distinction of epithelioid, biphasic, and sarcomatoid mesothelioma; recognition of morphologic variants and patterns; and recognition of common morphologic pitfalls; (2) molecular pathogenesis of mesothelioma; (3) application of immunohistochemical markers to establish mesothelial lineage and distinguish mesothelioma from common morphologic differentials; (4) application of ancillary studies to distinguish benign from malignant mesothelial proliferations, including BAP1 and MTAP immunostains; novel immunomarkers such as Merlin and p53; fluorescence in situ hybridization (FISH) for homozygous deletion of CDKN2A; and novel molecular assays; (5) practical recommendations for routine reporting of mesothelioma, including grading epithelioid mesothelioma and other prognostic parameters; (6) diagnosis of mesothelioma in situ; (7) cytologic diagnosis of mesothelioma, including use of immunostains and molecular assays; and (8) features of nonmalignant peritoneal mesothelial lesions.
A complement C4–derived glycopeptide is a biomarker for PMM2-CDG
Garapati, Kishore , Budhraja, Rohit , Saraswat, Mayank , Joshi, Neha , Sachdeva, Gunveen S. , Jain, Anu, Ligezka, Anna N. , Radenkovic, Silvia , Ramarajan, Madan Gopal , Udainiya, Savita, Raymond, Kimiyo , Lam, Christina , Edmondson, Andrew C. , Sarafoglou, Kyriakie , Larson, Nicholas B. , Kim, Jinyong, Edmondson, Andrew C , Larson, Nicholas B , Joshi, Neha S , Ramarajan, Madan G , Garapati, Kishore , Kim, Jin Yong , He, Miao , Larson, Austin , Freeze, Hudson H. , Schultz, Matthew , Kozicz, Tamás , Morava, Éva , Pandey, Akhilesh

Mayo Clinic

JCI Insight | April 7, 2024 | Volume: 9 | Issue: 7 | Pages: No page available

10.1172/jci.insight.172509 | PMID 38587076 Get It

BACKGROUND Diagnosis of PMM2-CDG, the most common congenital disorder of glycosylation (CDG), relies on measuring carbohydrate-deficient transferrin (CDT) and genetic testing. CDT tests have false negatives and may normalize with age. Site-specific changes in protein N-glycosylation have not been reported in sera in PMM2-CDG. METHODS Using multistep mass spectrometry–based N-glycoproteomics, we analyzed sera from 72 individuals to discover and validate glycopeptide alterations. We performed comprehensive tandem mass tag–based discovery experiments in well-characterized patients and controls. Next, we developed a method for rapid profiling of additional samples. Finally, targeted mass spectrometry was used for validation in an independent set of samples in a blinded fashion. RESULTS Of the 3,342 N-glycopeptides identified, patients exhibited decrease in complex-type N-glycans and increase in truncated, mannose-rich, and hybrid species. We identified a glycopeptide from complement C4 carrying the glycan Man 5 GlcNAc 2 , which was not detected in controls, in 5 patients with normal CDT results, including 1 after liver transplant and 2 with a known genetic variant associated with mild disease, indicating greater sensitivity than CDT. It was detected by targeted analysis in 2 individuals with variants of uncertain significance in PMM2 . CONCLUSION Complement C4–derived Man 5 GlcNAc 2 glycopeptide could be a biomarker for accurate diagnosis and therapeutic monitoring of patients with PMM2-CDG and other CDGs. FUNDING U54NS115198 (Frontiers in Congenital Disorders of Glycosylation: NINDS; NCATS; Eunice Kennedy Shriver NICHD; Rare Disorders Consortium Disease Network); K08NS118119 (NINDS); Minnesota Partnership for Biotechnology and Medical Genomics; Rocket Fund; R01DK099551 (NIDDK); Mayo Clinic DERIVE Office; Mayo Clinic Center for Biomedical Discovery; IA/CRC/20/1/600002 (Center for Rare Disease Diagnosis, Research and Training; DBT/Wellcome Trust India Alliance)
Highly Sensitized Candidates Remain at Risk for Microvascular Inflammation Even When Donor-specific Antibody Is Avoided: A Matched Cohort Study
Balakrishnan, Suryanarayanan, Alexander, Mariam P., Cornell, Lynn D. , Kukla, Aleksandra , Agrawal, Amogh, Stegall, Mark, Cornell, Lynn , Agrawal, Amogh , Gandhi, Manish J. , Bentall, Andrew , Stegall, Mark D. , Schinstock, Carrie A.

Mayo Clinic

Transplantation | April 5, 2024 | Volume: 108 | Issue: 9 | Pages: 1986-1993

10.1097/tp.0000000000005011 | PMID 38578704 Get It

Background. Microvascular inflammation (MVI) is a key feature of antibody-mediated rejection (AMR) among patients with HLA donor-specific antibody (DSA), but MVI at AMR thresholds (Banff glomerulitis [g] + peritubular capillaritis [ptc] score ≥ 2) without DSA has been increasingly recognized. We aimed to determine the incidence of MVI among highly sensitized kidney transplant recipients without DSA. Methods. We performed a single-center, retrospective, matched cohort study comparing outcomes of kidney transplant recipients with cPRA ≥90% with preexisting DSA (n = 49), cPRA ≥90% without preexisting DSA (n = 47), and matched controls with cPRA = 0 without preexisting DSA (n = 49). Controls were matched by age, donor type, and transplant date. Indication and surveillance biopsies combined with annual de novo DSA screening were obtained. Results. Kidney transplant recipients with a cPRA ≥90% and no evidence of preexisting or de novo DSA had a higher incidence of MVI (glomerulitis + peritubular capillaritis ≥ 2) than patients with cPRA = 0 [35% (17/49) versus 12% (6/49), P = 0.0003] over a median (interquartile range) follow-up of 5 (4–6) y posttransplant. Among this cPRA ≥90% group without DSA, MVI persisted in 54% of cases on follow-up biopsy (7/13), and 24% (4/13) of cases developed transplant glomerulopathy (Banff cg score > 0). Conclusions. Highly sensitized transplant recipients have a high incidence of persistent and progressive MVI, even without DSA. The mechanisms underlying these histologic features needs to be elucidated, but this information is important to consider when making decisions about transplantation among highly sensitized individuals.
Abstract CT136: Phase Ib study of siltuximab and spartalizumab in advanced pancreatic cancer
Gbolahan, Olumide B., Coleman, Kathleen, Cao, Yichun , Kane, Sujata , Craven, Sarah, Greene, Emily R. , McDonald, Andrew , Shaib, Walid L. , Akce, Mehmet , Diab, Maria , El‐Rayes, Bassel F. , El-Rayes, Bassel F , Gbolahan, Olumide B , Alese, Olatunji B. , Coleman, Kathleen M., Horvat, Natalie K. , Wu, Christina , Switchenko, Jeffrey M. , Lesinski, Gregory B

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: CT136-CT136

10.1158/1538-7445.am2024-ct136 Get It

Abstract Background: Pancreatic adenocarcinoma (PDAC) is an aggressive malignancy with dismal prognosis. Most patients present with advanced stages. Heightened levels of serum interleukin-6 (IL-6) are associated with carcinogenesis, immune suppression, and poor prognosis in PDAC. Preclinical data of dual inhibition of IL-6 and programmed death ligand-1 (PD-L1) facilitates CD8+ T-cell migration into pancreatic tumors and was effective in controlling tumor growth in syngeneic and genetically engineered PDAC mouse models. Siltuximab (Sil) is a chimeric monoclonal antibody which targets the IL-6 molecule specifically. Spartalizumab (Sparta) is a high-affinity ligand-blocking humanized IgG4 antibody against the PD-1 receptor. We developed a phase Ib/II trial to evaluate the safety, immunogenicity and preliminary antitumor activity of Sil and Sparta in metastatic PDAC (mPDAC). Methods: Patients (pts) with mPDAC who have progressed on at least one line of systemic chemotherapy were eligible for the trial. Other selected inclusion criteria were ≥18 years of age, ECOG PS 0-1 and measurable disease per RECIST v1.1. The phase Ib trial design is standard 3+3, with a primary endpoint of recommended phase II dose (RP2D). An additional 24 patients were planned for an expansion cohort. Sil was administered at escalating dose levels of 6 mg/kg (DL1) and 11 mg/kg (DL2), in combination with Sparta at 300 mg IV on day 1 of each 21-day cycle. Key secondary endpoints included overall response rate (ORR = CR + PR), progression-free survival (PFS) and overall survival (OS). Results: We enrolled 4 patients on DL1 and escalated to DL2/RP2D in the absence of a dose limiting toxicity (DLT). A total of 31 patients were subsequently treated at the RP2D (escalation + expansion). The median age was 68 years, 42% were male. Majority were White (63%) and 20% were Black. About 43% had head of pancreas primary tumors and 86% had liver involvement. The median number of lines of prior therapy was 3 (range 1-4). There was no objective response among the 4 patients on DL1; 1 had stable disease (SD) for 11 weeks as best response. 17 of 31 patients on RP2D had only a baseline assessment and came off study for progression of disease, prior to follow-up imaging assessment for response evaluation. Of the 14 RP2D patients with a follow-up assessment, ORR was 0% (3 were SD and 11 had progression of disease (PD) as best response), mPFS - 2.2 mos (95% CI: 1.9, 2.6), mOS - 5.5mos (95% CI: 2.8, 6.5). Treatment related adverse events (TRAEs) of any grade included fatigue (23%), anemia (18%), and increased liver enzymes (9.5%). There were no grade 4-5 TRAEs. Conclusions: The combination Sil/Sparta had an acceptable safety profile but did not elicit responses in advanced PDAC pts. Correlative studies using paired biopsies and blood are ongoing to determine how dual IL-6/PD-1 blockade impacts stromal and immune biomarkers in relationship to the clinical outcome measures. Funding and medications for the study were provided by Novartis and Recordati Rare Diseases Inc (NCT04191421) and NIH/NCI (R21CA266088). Citation Format: Olatunji B. Alese, Olumide Gbolahan, Kathleen M. Coleman, Yichun Cao, Sujata Kane, Sarah Craven, Emily Greene, Natalie Horvat, Andrew McDonald, Walid L. Shaib, Christina S. Wu, Mehmet Akce, Maria Diab, Jeffrey M. Switchenko, Gregory B. Lesinski, Bassel F. El-Rayes. Phase Ib study of siltuximab and spartalizumab in advanced pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT136.